Human & Experimental Toxicology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Çetin, M.
Right arrow Articles by Ünlühizarci, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Çetin, M.
Right arrow Articles by Ünlühizarci, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Human & Experimental Toxicology, Vol. 18, No. 3, 137-140 (1999)
DOI: 10.1177/096032719901800301

Frequency of flutamide induced hepatotoxicity in patients with prostate carcinoma

Mustafa Çetin

Section of Hematology/Oncology, University of Erciyes, Kayseri, Turkey

Deniz Demirci

Department of Urology, University of Erciyes, Kayseri, Turkey

Ali Ünal

Section of Hematology/Oncology, University of Erciyes, Kayseri, Turkey

Mustafa Altinbas

Section of Hematology/Oncology, University of Erciyes, Kayseri, Turkey

Muhammed Güven

Department of Medicine, University of Erciyes, Kayseri, Turkey

Kürsat Ünlühizarci

Department of Medicine, University of Erciyes, Kayseri, Turkey

To identify and describe the frequency and severity of hepatotoxicity in patients who received flutamide therapy for prostate cancer, 22 patients were treated with the combination of flutamide and goserilin or orchiectomy. After diagnosis and staging of prostate cancer, baseline results were obtained for a set of five liver function tests (LF Ts). Hepatotoxicity was assessed according to the WHO criteria. After initiation of flutamide therapy, LF Ts were performed at 4, 8 and 12 weeks and every 2 months thereafter. Severe hepatotoxicity appeared in two of 22 (9%) patients. Following the discontinuation of flutamide, one patient died due to acute liver failure. On the other patient an improvement of LF Ts occurred after cessation of flutamide. The observed severe hepatotoxicity in two of 22 (9%) patients occurred more frequent than is predicted in the literature. Patients treated with flutamide, having symptomatic or asymptomatic liver enzyme elevations, should be taken off therapy as soon as possible.

Key Words: flutamide • hepatotoxicity


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
P. Kang, D. Dalvie, E. Smith, S. Zhou, A. Deese, and J. A. Nieman
Bioactivation of Flutamide Metabolites by Human Liver Microsomes
Drug Metab. Dispos., July 1, 2008; 36(7): 1425 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
P. Kang, D. Dalvie, E. Smith, S. Zhou, and A. Deese
Identification of a Novel Glutathione Conjugate of Flutamide in Incubations with Human Liver Microsomes
Drug Metab. Dispos., July 1, 2007; 35(7): 1081 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. J. Coe, S. D. Nelson, R. G. Ulrich, Y. He, X. Dai, O. Cheng, M. Caguyong, C. J. Roberts, and J. G. Slatter
PROFILING THE HEPATIC EFFECTS OF FLUTAMIDE IN RATS: A MICROARRAY COMPARISON WITH CLASSICAL ARYL HYDROCARBON RECEPTOR LIGANDS AND ATYPICAL CYP1A INDUCERS
Drug Metab. Dispos., July 1, 2006; 34(7): 1266 - 1275.
[Abstract] [Full Text] [PDF]